Simris Group AB Appoints ADC Expert Professor Andreas Pahl as Chief Executive Officer of its Subsidiary Simris Biologics GmbH
Simris Group AB (SIMRIS B) today announced the appointment of Professor Andreas Pahl as Chief Executive Officer of Simris Biologics GmbH, its wholly owned subsidiary based in Berlin, Germany. Professor Pahl will begin his assignment immediately. Simris Biologics develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies.
Professor Pahl will lead the advancement of the Company’s Microcystin platform and help shape future development programs in line with the strategic direction selected by the Board. He brings deep expertise in the development and commercialization of antibody-drug conjugates (ADCs) following his previous roles at Heidelberg Pharma AG.
